113 related articles for article (PubMed ID: 2128828)
1. Combination studies with leuprolide.
Crawford ED
Eur Urol; 1990; 18 Suppl 3():30-3. PubMed ID: 2128828
[TBL] [Abstract][Full Text] [Related]
2. Leuprolide with and without flutamide in advanced prostate cancer.
Crawford ED; Blumenstein BA; Goodman PJ; Davis MA; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA
Cancer; 1990 Sep; 66(5 Suppl):1039-44. PubMed ID: 2118417
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Benson R; Dorr FA; Blumenstein BA; Davis MA; Goodman PJ
N Engl J Med; 1989 Aug; 321(7):419-24. PubMed ID: 2503724
[TBL] [Abstract][Full Text] [Related]
4. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
8. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
Crawford ED; Allen JA
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):961-3. PubMed ID: 2126738
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
Crawford ED; Goodman P; Blumenstein B
Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
[No Abstract] [Full Text] [Related]
10. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
Benson RC; Crawford ED; Eisenberger MA; McLeod DG; Spaulding JT; Dorr FA
Semin Oncol; 1991 Oct; 18(5 Suppl 6):9-12. PubMed ID: 1948121
[TBL] [Abstract][Full Text] [Related]
11. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
12. Total androgen blockade: the United States experience.
Benson RC
Eur Urol; 1993; 24 Suppl 2():72-6. PubMed ID: 8262130
[TBL] [Abstract][Full Text] [Related]
13. Flutamide for prostate cancer.
Med Lett Drugs Ther; 1989 Jul; 31(797):72. PubMed ID: 2501635
[No Abstract] [Full Text] [Related]
14. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
16. The use of flutamide in hormone-refractory metastatic prostate cancer.
McLeod DG; Benson RC; Eisenberger MA; Crawford ED; Blumenstein BA; Spicer D; Spaulding JT
Cancer; 1993 Dec; 72(12 Suppl):3870-3. PubMed ID: 8252506
[TBL] [Abstract][Full Text] [Related]
17. Flutamide approved for prostate cancer.
Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
[No Abstract] [Full Text] [Related]
18. Luteinizing hormone releasing hormone agonists: the US experience.
Nabors W; Crawford ED
J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
[TBL] [Abstract][Full Text] [Related]
19. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
20. Controversies in the treatment of metastatic prostate cancer.
McLeod DG; Crawford ED; Blumenstein BA; Eisenberger MA; Dorr FA
Cancer; 1992 Jul; 70(1 Suppl):324-8. PubMed ID: 1600494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
